Ceftobiprole
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections, Streptococcal Infections
Trial Timeline
Aug 1, 2007 → Apr 1, 2010
NCT ID
NCT01026636About Ceftobiprole
Ceftobiprole is a phase 1 stage product being developed by Johnson & Johnson for Staphylococcal Skin Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01026636. Target conditions include Staphylococcal Skin Infections, Streptococcal Infections.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01026558 | Phase 1 | Completed |
| NCT01026636 | Phase 1 | Completed |
| NCT01030731 | Phase 1 | Completed |
Competing Products
20 competing products in Staphylococcal Skin Infections